WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq:ENCO) (“Encorium”), a leader in the design and management of complex clinical trials and patient disease registries for the pharmaceutical, biotechnology and medical device industries, today announced the appointment of healthcare and life sciences industry veteran Paul J. Schmitt to its Board of Directors. Mr. Schmitt replaces Earl M. Collier, Jr., who has served as a Director since March 2002, and has tendered his resignation from the Company’s Board of Directors effective immediately. Mr. Collier advised the Board of Directors that he was resigning to focus more attention on his current business interests. Mr. Collier’s resignation letter contained no disagreement with management concerning any matter relating to the Company’s operations, policies or practices.
